Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans

Individuals who rely on public health payers to access new medicines can access fewer innovative medicines and must wait longer in Canada compared to major markets around the world. New medicines/indications approved by Health Canada and reviewed for eligibility for reimbursement by the Common Drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Salek, Sam, Lussier Hoskyn, Sarah, Johns, Jeffrey Roy, Allen, Nicola, Sehgal, Chander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449480/
https://www.ncbi.nlm.nih.gov/pubmed/30983993
http://dx.doi.org/10.3389/fphar.2019.00196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449480/
https://www.ncbi.nlm.nih.gov/pubmed/30983993
http://dx.doi.org/10.3389/fphar.2019.00196

Ejemplares similares